ARDX

Ardelyx's stock price experienced significant fluctuations over the past six months, declining by 33.60% between October 2025 and October 2026, and by 35.38% over the past year. Key events included the Q1 2026 earnings report on April 30, 2026, where total product revenues increased by 38% year-over-year to $93.4 million, with IBSRELA revenue growing by 58% to $70.1 million and XPHOZAH revenue at $23.3 million, and the company reiterated full-year guidance. The Q2 2026 earnings report on August 6, 2026, showed record total product revenue of $118.1 million, a 31% year-over-year growth, but the company revised IBSRELA revenue guidance downwards and withdrew long-term XPHOZAH guidance due to increased payer utilization-management processes and evolving market dynamics, leading to an approximately 18% drop in ARDX shares. In September 2026, Ardelyx participated in investor conferences, where management reiterated expectations for nearly $500 million in revenue for 2026 and profitability in 2027, while acknowledging ongoing payer and pharmacy access hurdles. At ASN Kidney Week 2026 (October 21-25, 2026), Ardelyx announced new data on hyperphosphatemia management, including real-world evidence on tenapanor's effectiveness, which resulted in a slight positive movement in the stock.